Coastal eye surgeons
Greenwich, Connecticut, 06830, United States
NCT Number: NCT06500416
Tecnis Symfony Optiblue EDOF IOL is the latest version of Tecnis Symfony IOL with a violet light filter (VLF), which blocks short-wavelength light and improves the quality of vision while minimizing visual disturbances. The present study aims to assess the visual outcomes at distance, intermediate, and near following cataract surgery and implantation of Tecnis Symfony Optiblue IOL in patients with retinal comorbidities.
Trial opening soon.
Get Notified50 year–85 year
All sexes
Interventional
Not applicable
Greenwich, Connecticut, 06830, United States
Extended depth of focus (EDOF) IOLs, on the other hand, are based on the principle of creating a single-elongated focal point to enhance the depth of focus (DOF) and eliminate the overlapping of near and far images caused by traditional multifocal IOLs, thus generating a lower incidence of halos and glare. The Tecnis Symfony (Johnson & Johnson Vision) EDOF IOL incorporates a diffractive echelette design to increase the range of vision. The achromatic technology corrects chromatic aberration and increases retinal image contrast.
The latest version of the Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts. As such, the present study aims to assess the visual outcomes at distance, intermediate and near following implantation of violet light filtering Tecnis Symfony Optiblue EDOF IOLs in patients with retinal comorbidities undergoing cataract surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts.
Time frame: 3 months
Mean binocular uncorrected visual acuity at distance
Time frame: 3 months
Mean binocular uncorrected visual acuity at intermediate
Time frame: 3 months
Mean binocular uncorrected visual acuity at near
Time frame: 3 months
Mean monocular uncorrected visual acuity at distance
Time frame: 3 months
Mean monocular corrected visual acuity at distance
Time frame: 3 months
Mean monocular uncorrected visual acuity at intermediate
Time frame: 3 months
Mean monocular distance corrected visual acuity at intermediate
Time frame: 3 months
Mean monocular uncorrected visual acuity at near
Time frame: 3 months
Mean monocular distance corrected visual acuity at near
Time frame: 3 months
Mean binocular corrected visual acuity at distance
Time frame: 3 months
Mean binocular distance-corrected visual acuity at intermediate
Time frame: 3 months
Mean binocular distance-corrected visual acuity at near
Trial opening soon.
Get NotifiedCoastal Eye Surgeons PLLC
Other
Visual Outcomes Following Implantation of Tecnis Symfony Opti-Blue EDOF IOL in Patients With Mild to Moderate Retinal Ocular Comorbidities
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07821827
Cataract, Eye Diseases
View Trial DetailsNCT07790887
Cataract, Eye Diseases
Sioux Falls, South Dakota, United States
View Trial DetailsNCT07441616
Cataract, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Leuven, Belgium
View Trial DetailsNCT07755189
Cataract, Eye Diseases
Shanghai, Shanghai Municipality, China
View Trial Details